Windtree Therapeutics Q2 2025 Earnings Report

Windtree Therapeutics EPS Results

• Actual EPS: -$3.06
• Consensus EPS: -$99.00
• Beat/Miss: Beat by +$95.94
• One Year Ago EPS: N/A

Windtree Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $3.00 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Windtree Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/19/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 19, 2025
• Conference Call Time: 4:00PM ET

Windtree Therapeutics (NASDAQ:WINT) is a clinical-stage biotechnology company developing innovative therapies for acute cardiovascular and pulmonary conditions. The company leverages its proprietary KL4 surfactant technology to address diseases marked by surfactant deficiency or dysfunction, with a primary focus on acute respiratory distress syndrome (ARDS) in adults and respiratory distress syndrome (RDS) in premature infants.

The company’s lead platform comprises synthetic peptide‐based surfactants designed to restore lung function by reducing surface tension in the alveoli. Windtree’s pipeline includes aerosolized and intratracheal formulations intended for rapid distribution in the lung, including programs that have advanced through preclinical studies and early-stage clinical trials. These programs aim to offer an alternative to animal-derived surfactants and to target patient populations with significant unmet medical needs.

Headquartered in Warrington, Pennsylvania, Windtree collaborates with academic research centers and clinical investigators across the United States and Europe to conduct its development programs. The company’s activities encompass formulation optimization, toxicology testing, and multi-site clinical evaluations, supported by partnerships that extend its reach into critical care and neonatal intensive care settings.

Under the leadership of President and CEO Michael Ott, Windtree maintains a management team with extensive experience in drug development, regulatory affairs and commercial strategy. The organization is committed to advancing its pipeline through regulatory interactions and clinical milestones in pursuit of therapies that can improve outcomes for patients with serious cardiopulmonary disorders.